Skip to content

Source filing unavailable

Q3 2011 · —
Revenue$73.29M±0.0% vs Q3 2010+13.5% vs Q2 2011
Net Income$32.48M±0.0% vs Q3 2010−2.2% vs Q2 2011
EPS Diluted$0.69±0.0% vs Q3 2010−2.8% vs Q2 2011
Gross Profit$68,315,000±0.0%
Operating Income$33,704,000+133.4%
Operating Cash Flowderived$46,053,000+149.1%
Free Cash Flowderived$45,691,000+151.5%
Margins · derived
Gross margin93.2%±0.0 pt vs Q3 2010
Operating margin46.0%+26.3 pt vs Q3 2010
Net margin44.3%±0.0 pt vs Q3 2010

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ3 2011Q3 2010
Revenue$73.29M$73.29M
Net Income$32.48M$32.48M
EPS Diluted$0.69$0.69

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR